Brentuximab vedotin - Seattle Genetics/Takeda

Drug Profile

Brentuximab vedotin - Seattle Genetics/Takeda

Alternative Names: Adcetris; Anti-CD30-MMAE; Anti-CD30-monoclonal-antibody-cAC10-auristatin-E-conjugate; Auristatin-E-anti-CD30-monoclonal-antibody-cAC10-conjugate; cAC10-vcMMAE; MMAE-anti-CD30; SGN-35

Latest Information Update: 05 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Seattle Genetics; Stanford University
  • Developer Bristol-Myers Squibb; Celgene Corporation; Dana-Farber Cancer Institute; Fondazione Italiana Linfomi; Fox Chase Cancer Center; Immune Tolerance Network; Lymphoma Academic Research Organisation; Massachusetts General Hospital; National Cancer Institute (USA); National Institute of Allergy and Infectious Diseases; Seattle Genetics; Stanford University; Takeda; Takeda Oncology
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hodgkin's disease; Non-Hodgkin's lymphoma; Anaplastic large cell lymphoma; Peripheral T-cell lymphoma; Cutaneous T cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anaplastic large cell lymphoma; Hodgkin's disease
  • Preregistration Cutaneous T cell lymphoma
  • Phase III T cell lymphoma
  • Phase II Diffuse large B cell lymphoma; Germ cell and embryonal neoplasms; Mesothelioma; Mycosis fungoides; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Sezary syndrome
  • Phase I/II Diffuse scleroderma
  • Phase I Graft-versus-host disease
  • Discontinued Leukaemia; Multiple myeloma; Solid tumours; Systemic lupus erythematosus

Most Recent Events

  • 02 Oct 2017 Brentuximab vedotin receives Breakthrough Therapy status for Hodgkin's disease (Combination therapy, First-line therapy) in USA
  • 02 Oct 2017 Seattle Genetics announces intention to submit sBLA to the US FDA for Hodgkin's disease (First-line therapy) before the end of 2017
  • 20 Sep 2017 Phase-I/II clinical trials in Diffuse scleroderma in USA (IV) (NCT03222492)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top